Interstitial Lung Disease Questionnaire
Overview
1. To evaluate the health status of patients with Interstitial Lung Disease (ILD), and how this varies between subgroups of ILD. 2. To investigate the prevalence of symptoms, anxiety, depression, and sleep-disordered breathing within ILD patient population. 3. To assess the economic impact of ILD. 4. To understand how self-aware ILD patients are regarding their treatment/management. 5. To compare the demographic details, including smoking status and occupational history, of patients with interstitial lung disease
Full Title of Study: “Questionnaire Study for Patients With Interstitial Lung Disease”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: November 2013
Detailed Description
Primary endpoint • Health status in the target populations, as determined by the K-BILD questionnaire. Secondary endpoints - – Severity of dyspnoea suffered by patients – Prevalence of anxiety and depression – Prevalence of sleep-disordered breathing symptoms – Degree of self-awareness displayed by patients – The costs associated with ILD from a patient and healthcare perspective. – Demographic details
Arms, Groups and Cohorts
- Idiopathic Pulmonary Fibrosis
- Questionnaire evaluation
- Non Idiopathic Pulmonary Fibrosis
- Questionnaire evaluation
- Sarciodosis
- Questionnaire evaluation
- Healthy Controls
- Questionnaire evaluation
Clinical Trial Outcome Measures
Primary Measures
- Difference in the Mean K-BILD score between the 4 groups
- Time Frame: Baseline
- HRQL
Secondary Measures
- Severity of dyspnoea suffered by patients
- Time Frame: Baseline
- Prevalence of anxiety and depression
- Time Frame: Baseline
- Prevalence of sleep-disordered breathing symptoms
- Time Frame: Baseline
- Degree of self-awareness displayed by patients
- Time Frame: Baseline
- The costs associated with ILD from a patient and healthcare perspective
- Time Frame: Baseline
- Demographic details
- Time Frame: Baseline
Participating in This Clinical Trial
Inclusion Criteria
- Male or female – Age greater than 18 years of age – Any smoking status – Diagnosis of Interstitial Lung Disease as defined below – Full pulmonary lung function tests and routine immunological tests undertaken within 6 months of entry into study Exclusion Criteria:
• Unable to give consent to take part
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- University of East Anglia
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Andrew M Wilson, Principal Investigator, University of East Anglia
- Overall Contact(s)
- Andrew M Wilson, MRCP, MD, 00441603591257, a.m.wilson@uea.ac.uk
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.